Digital Biomarkers For Alzheimer’s Disease Summit
date15 July 2020
Quanterix Presentation: (Time TBD)
Novel Simoa p-tau181 Blood Immunoassay to Support Research, Therapeutics Development and Clinical Care of Alzheimer’s Disease
Tatiana Plavina, PhD
Quanterix VP, Clinical Strategy
Identifying and Validating Biomarkers to Develop Truly Disease Modifying Therapeutics for Alzheimer’s Disease
The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement.
With an emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves into blood-based biomarkers, neuroinflammatory markers, NFL, microglial activation, exosomes and CSF synaptic biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s.
Share this page